The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approvals for Novo’s preventive hemophilia A therapy and seven other medicines in a September wave of opinions. The package also included multiple label expansions, signaling continued momentum for EU-wide access to new options across hematology and other therapeutic areas.